Deflazacort: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Deflazacort. Educational only — not medical advice.
Labeled uses
Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
Source: FDA labeling via NIH DailyMed (set 2fac1332…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.